SAGE Therapeutics

Biotech & Life Sciences · Raleigh, United States · Founded 2010 · IPO 2014

Develops and delivers novel medicines for most debilitating and disabling central nervous system disorders

Valuation $191M

Revenue $70M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Knowledge graph

News Tortugas Neuroscience launches with $106M for mid-stage CNS pipeline Apr 21, 2026

Talent graph

SAGE Therapeutics's talent

Book a demo to see the people

Employees mapped 193 incl. 6 AI specialists

Founders /100 quality score

Key operators 31 quality /100

Potential founders likely future founders

Startup mafia 5 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on SAGE Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Third Rock Ventures

Series B+ 5 investors entered at this stage

ARCH Venture Partners

Washington University in St. Louis

Foresite Capital

OrbiMed

EcoR1 Capital

SAGE Therapeutics mafia

Startups founded by SAGE Therapeutics alumni

Former SAGE Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Praxis Precision MedicinesEst. 2015

Kiran ReddyUnited States

Signal score95

Model MedicinesEst. 2019

SRSean RussellUnited States

Signal score78

Voyager TherapeuticsEst. 2014

Steven PaulUnited States

Signal score66

Nido BiosciencesEst. 2018

Jamil BegUnited States

Signal score61

Tortugas NeuroscienceEst. 2024

Albert J. RobichaudUnited States

Signal score58

Book a demo to explore the full alumni network →

Global footprint

Where SAGE Therapeutics has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States97.5%

🇬🇧 United Kingdom1%

🇨🇦 Canada0.7%

🇪🇬 Egypt0.4%

4 countries shown

Web traffic by country

4.8K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Patent intelligence

$273M patent portfolio · 124 active families

Estimated portfolio value

$273M

143.0% of market cap · 21.1× smaller than top peer Ablynx ($5.8B)

124 active patent families

Where SAGE Therapeutics innovates Autism disorderAutism spectrum disorderDiseaseMedicinal chemistryNeuroactive steroid

Where SAGE Therapeutics concentrates vs peers

Each axis is a top-10 topic across SAGE Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about SAGE Therapeutics

An AI-synthesized read of the highest-engagement posts about SAGE Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SAGE Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles